BridgeMD
Efficacy and Safety of ANB032 in the Treatment of Subjects with Atopic Dermatitis
EU CTIS ID: 2023-503522-40-01
What this study is testing
To assess the clinical efficacy of ANB032 versus placebo in subjects with moderate to severe atopic dermatitis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female aged 18 to 65 years and in good general health
- Moderate or severe atopic dermatitis continuously for at least 6 months prior to randomization
- History of inadequate response to both topical corticosteroids and topical calcineurin inhibitors or for whom topical treatments are otherwise medically inadvisable
- EASI score >=16 at Screening and at Randomization
- vIGA-AD score >=3 at Screening and at Randomization
- AD-involved BSA>=10% at Screening and at Randomization
You likely can't join if
- Any factors that in the Investigator's opinion would predispose the subject to develop an infection
- Known or suspected congenital or acquired immunodeficiency state, or condition that would compromise the subject's immune status
- Not able to tolerate SC drug administration
- Tanning booth use or extended sun exposure that could affect disease severity or interfere with disease assessments within 4 weeks before Randomization
- Received or plans to initiate during the study any of the following prescribed medications or therapies: Systemic Janus kinase (JAK) inhibitors at any time prior to Day 1, Immunomodulatory biologic agents received within 12 weeks or 5 half lives (t1/2; whichever is longer) before Day 1, Phototherapy treatment or laser therapy that could affect disease severity or interfere with disease assessments within 4 weeks before Day 1, Systemic therapy for AD, including but not limited to, corticosteroids, methotrexate, cyclosporine, azathioprine, phosphodiesterase type 4 (PDE 4) inhibitors, IFN γ, and mycophenolate mofetil within 4 weeks before Day 1, Use of topical treatments for AD including but not limited to corticosteroids, tacrolimus, pimecrolimus, JAK inhibitors, or PDE-4 inhibitors within 14 days before Day 1, Live or live attenuated vaccines within 12 weeks before Day 1
The study team makes the final eligibility decision.
Where it's taking place
- New Zealand
- Canada
- United States
- Georgia
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include New Zealand; Canada; United States; Georgia; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.